🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Muscle Growth5 cited studies

GHRP-2

Synthetic ghrelin-receptor agonist — robust GH secretagogue used in research and lean-mass protocols.

Also known as: GHRP 2 · Pralmorelin
SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

GHRP-2 is a synthetic peptide designed to stimulate the body's natural production of growth hormone, often used in research for performance, recovery, and body composition contexts. It enhances GH pulse amplitude, supports lean tissue, accelerates recovery, and improves sleep and immune function.

Mechanism of action

Agonist at the growth hormone secretagogue receptor (GHSR-1a / ghrelin receptor) on pituitary and hypothalamic neurons. Drives strong GH release; minor cortisol and prolactin elevation possible at higher doses (greater than ipamorelin).

Half-life: ~15–60 minutes.

Evidence summary

Established as a strong GH secretagogue in healthy adults and GH-deficient pediatric populations. Pharmacology and dose-response work characterised in the Bowers / Bowers-Howard line of research; food-animal data confirms growth-promoting effect.

Pantheon dosing guide

Application
Subcutaneous injection.
BAC Water
3 ml
Dose
5 mg: 10 units (166 mcg). 10 mg: 10 units (333 mcg).
Frequency & Cycle Length
5 days on / 2 off. 6 weeks.
Timing
Patients Preference.
Key Benefits
Stimulates growth hormone release. Increases muscle mass. Supports tissue repair and recovery. Reduces inflammation. Promotes fat loss. Boosts immune function. Improves sleep quality.

Additional research protocol context

The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.

  • 100–300 mcg subcutaneous, 2–3× daily
  • Often paired with CJC-1295 for amplified GH pulse
  • 12-week cycles, with periodic IGF-1 monitoring

Side effects & safety

  • Increased appetite (ghrelin agonism)
  • Mild cortisol or prolactin elevation possible
  • Injection-site irritation

Cited studies

  1. (2024). Robust growth hormone responses to GH-releasing peptide 2 in adolescents. Journal of Pediatric Endocrinology and Metabolism (PubMed).
    Read source ↗
  2. (2001). Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. Journal of Clinical Endocrinology & Metabolism.
    Read source ↗
  3. (1996). GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. Journal of Pediatric Endocrinology and Metabolism.
    Read source ↗
  4. (2000). The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domestic Animal Endocrinology.
    Read source ↗
  5. (2004). Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung.
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.